Study of the effect of low-dose aspirin on physiological and biochemical parameters of patients with diabetes and hypertension in Thi- Qar governorate

Husam Abed  Hashim; Mohannad Abdulrazzaq Gati

doi:10.53730/ijhs.v6nS5.7616

Authors

Husam Abed Hashim University of Thi-Qar, College of Science, Department of Biology, Iraq
Mohannad Abdulrazzaq Gati University of Thi-Qar, College of Science, Department of Biology, Iraq

Keywords:

Aspirin, diabetes mellitus, hypertension, platelets, dyslipidemia

Abstract

Background: Aspirin has been widely used around the world for more than 100 years. Aspirin has a wide range of biological activities and clinical applications that interact with cellular signaling and metabolism, especially in diabetics and hypertensive. It acts as an antiplatelets drug. Objectives: To compare the effects of aspirin on patients with diabetes and high blood pressure who use aspirin with those who do not use aspirin by studying the effects of aspirin on a group of chemical, immunological, and hormonal tests and knowing the extent of the effect of aspirin on those parameters to determine the usefulness of aspirin for those who use it. Methodology: In the current study, only male patients with diabetes and hypertension were selected, meaning the same patient with type 2 diabetes and hypertension was divided into three groups. The first group had diabetes-hypertension and used aspirin, the second group had diabetes-hypertension and did not use aspirin, and the third group was the control group. Samples were taken and tests were conducted at the specialized center for endocrinology and diabetes after obtaining the patient's consent on a special form.

Downloads

Download data is not yet available.

References

Alsop, R. J. et al. (2015) ‘Biochimica et Biophysica Acta Aspirin inhibits formation of cholesterol rafts in fl uid lipid membranes’, ELSIVER, 1848(11), pp. 805–812.

Aung, T. (2017) The Role of Omega-3 Fatty Acids and Aspirin in the and Biochemical effectiveness of Omega-3 Fatty Acids and Aspirin in the ASCEND trial. University of Oxford.

Azegami, T. et al. (2021) ‘Blood Pressure Tracking From Childhood to Adulthood’, 9(9), pp. 1–7.

Biff F. Palmer, M.D., and Deborah J. Clegg, P. D. (2020) ‘Salicylate Toxicity’, The New England Journal of Medicine, med(382), pp. 2544–55.

Buse, J. B. et al. (2007) ‘Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association’, Diabetes Care, 30(1), pp. 162–172.

Chawla, A., Chawla, R. and Jaggi, S. (2016) ‘Review Article Microvasular and macrovascular complications in diabetes mellitus : Distinct or continuum ?’, Indian Journal of Endocrinology and Metabolism, (20), pp. 546–53.

Chowdhury, T. A. (2014) Diabetes Management in Clinical Practice.

Collet, J. P. et al. (2006) ‘Altered Fibrin Architecture Is Associated With Hypofibrinolysis and Premature Coronary Atherothrombosis’, Arterioscler Thromb Vasc Biol, 26(11), pp. 2567–2574.

Collins, R. et al. (2009) ‘Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials’, The Lancet, 373(9678), pp. 1849–1860.

Dunlay, S. M. et al. (2015) ‘Activities of Daily Living and Outcomes in Heart Failure’, pp. 261–268.

Emerging, T. and Factors, R. (2010) ‘Diabetes mellitus , fasting blood glucose concentration , and risk of vascular disease : a collaborative meta-analysis of 102 prospective studies’, The Lancet, 375(9733), pp. 2215–2222.

Fu, J. et al. (2021) ‘Insulin ’ s actions on vascular tissues : Physiological effects and pathophysiological contributions to vascular complications of diabetes’, Molecular Metabolism, 52(4), pp. 1–11.

Gao, Z. et al. (2003) ‘Aspirin Inhibits Serine Phosphorylation of Insulin Receptor Substrate 1 in Tumor Necrosis Factor-treated Cells through Targeting Multiple Serine Kinases *’, Journal of Biological Chemistry, 278(27), pp. 24944–24950.

Gao1, J. Z. shiqing M. Z. liu1 hongjuan geng1 X. lu1 X. Z. hongjie li1 chenyuan gao2 X. Z. P. (2017) ‘Guided bone regeneration with asymmetric collagen-chitosan membranes containing aspirin- loaded chitosan nanoparticles’, International Journal of Nanomedicine, 12, pp. 8855–8866.

Gast, K. B. et al. (2012) ‘Insulin Resistance and Risk of Incident Cardiovascular Events in Adults without Diabetes : Meta-Analysis’, PLOS ONE, 7(12), pp. 1–8.

Gaziano, T. A. et al. (2009) ‘The global cost of nonoptimal blood pressure’, pp. 1472–1477.

Grossman, A. and Grossman, E. (2017) ‘Blood pressure control in type 2 diabetic patients’, Cardiovascular Diabetology, pp. 1–15.

Hinz, Burkhard; Renner, Bertold; Brune, K. et al. (2007) ‘Drug Insight : cyclo-oxygenase-2 inhibitors — a critical appraisal’, Nature, 3(10), pp. 552–560.

Hypertension, W. H. O. (2020) Hylertension, World Health Organization. Hypertension.

Id, C. B. et al. (2019) ‘Long-term performance of instrumental activities of daily living in young and middle- aged stroke survivors — Impact of cognitive dysfunction , emotional problems and fatigue’, pp. 1–14.

Laiteerapong, N. et al. (2019) ‘The Legacy Effect in Type 2 Diabetes : Impact of Early Glycemic Control on Future Complications ( The Diabetes & Aging Study )’, Diabetes Care, 42(3), pp. 416–426.

Levin, G. et al. (2010) ‘Glucose , Insulin , and Incident Hypertension in the Multi-Ethnic Study of Atherosclerosis’, American Journal of Epidemiology, 172(10), pp. 1144–1154.

Loss, D. B. et al. (2011) ‘Cellular Physiology and Biochemistr y Biochemistry Low Dose Aspirin Therapy Decreases Blood Glucose Levels but Does not Prevent Type I’, Cellular Physiology and Biochemistry, 28(9), pp. 923–932.

Mark Lambie, Mario Bonomini, Simon J. Davies, Domenico Accili, Arduino Arduini, V. Z. (2022) ‘Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis’, Trends Endocrinol Metab., 32(9), pp. 721–730.

Mawson, T. et al. (2017) ‘Mechanisms of erosion of atherosclerotic plaques’, Current Opinion in Lipidology, 28(5), pp. 434–441.

Ni, W. et al. (2015) ‘Serum lipids and associated factors of dyslipidemia in the adult population in Shenzhen’, Lipids in Health and Disease, 14(71), pp. 1–11.

NLM (2017) ‘Aspirin’, in National Center for Biotechnology Information, pp. 1–7.

Paseban, M. et al. (2019) ‘biomolecules Comparison of the Neuroprotective E ff ects of Aspirin , Atorvastatin , Captopril and Metformin in Diabetes Mellitus’, biomolecules, 9(3), pp. 1–12.

Rafeeq, A., Najam, R. and Hussain, S. Y. (2016) ‘Aspirin Associated Liver Toxicity – The Optimal Dose of Aspirin in Liver Insufficiency’, ijsrpub, 4(2), pp. 28–32.

Reaven, G. (2012) ‘Insulin Resistance and Coronary Heart Disease in Nondiabetic Individuals’, Arteriosclerosis, Thrombosis, and Vascular Biology is, 32(1), pp. 1754–1759.

Risk, N. C. D. and Collaboration, F. (2021) ‘Articles Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 : a pooled analysis of 1201 population-representative studies with 104 million participants’, 398.

Rodríguez, L. A. G. et al. (2020) ‘Effect of proton pump inhibitors on risks of upper and lower gastrointestinal bleeding among users of low-dose aspirin: A population-based observational study’, Journal of Clinical Medicine, 9(4), pp. 1–12.

Senarathne, R. U. H. N. D. R. H. S. Z. L. A. (2021) ‘Metabolic syndrome in hypertensive and non-hypertensive subjects’, Health Science Reports, 454(10), pp. 1–6.

Soriano, L. C. et al. (2013) ‘Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation’, Thrombosis and Haemostasis, 110(6), pp. 1298–1304.

Stanaway, J. D. et al. (2018) ‘Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Stu’, The Lancet, 392(10159), pp. 1923–1994.

Su, W. et al. (2019) ‘Hemoglobin A 1c , and Triglyceride – Glucose Index on’, Nutrients, 11(11), pp. 1–13.

Sun, Z. et al. (2009) ‘Prevalence of diabetes and impaired fasting glucose in hypertensive adults in rural China’, Acta Cardiologica, 64(3), pp. 351–356.

Tatsumi, Y. et al. (2019) ‘Fasting Blood Glucose Predicts Incidence of Hypertension Independent of HbA1c Levels and Insulin Resistance in Middle-Aged Japanese : The Saku Study’, American Journal of Hypertension, 32(12), pp. 1178–85.

Thabah, M. M. and Sharma, R. (2018) ‘Aspirin for primary prevention of cardiovascular disease events in diabetes: The balancing act?’, Journal of the Royal College of Physicians of Edinburgh, 48(4), pp. 332–333.

Undas, A. et al. (2007) ‘Antithrombotic properties of aspirin and resistance to aspirin : beyond strictly antiplatelet actions’, blood, 109(12), pp. 2285–2292.

Whelton, P. K. et al. (2018) ‘2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Pr’, Journal of the American College of Cardiology, 71(19), pp. e127–e248.

WHO (2016) GLOBAL REPORT ON DIABETES.

Xu, M. et al. (2009) ‘Association of arterial stiffness with HbA1c in 1 , 000 type 2 diabetic patients with or without hypertension’, Endocr, 36(7), pp. 262–267.

Yusuf, S. et al. (2019) ‘Articles Modifiable risk factors , cardiovascular disease , and mortality and low-income countries ( PURE ): a prospective cohort study’, 6736(19), pp. 1–14.